Akero’s Phase II Success Could Augur Brighter Days For NASH R&D
Executive Summary
With Akero’s FGF21 analog showing ability to reduce fibrosis and resolve non-alcoholic steatohepatitis, some analysts think classmate BIO89-100 could yield a better overall profile. NASH data are starting to pour in.
You may also be interested in...
Who Will Emerge As Best In Class Of The FGF21 Analogs In NASH?
Akero hopes to begin Phase III study of efruxifermin this year, with 89bio working to enter Phase III with pegozafermin in 2024. But just behind them, Boston Pharmaceuticals thinks it has a convenience and immunogenicity edge.
A Look Into The Future Of NASH
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.
A Look Into The Future Of NASH
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.